Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities

Author(s): Feng Huang, Tian Tian, Yizhe Wu, Jinxin Che, Haiyan Yang*, Xiaowu Dong*

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 21 , Issue 9 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Tumor cells frequently reprogram cellular metabolism from oxidative phosphorylation to glycolysis. Isocitrate dehydrogenase 2 (IDH2) has been intensively studied due to its involvement in the metabolic activity of cancer cells. Mutations in IDH2 promote neomorphic activity through the generation of oncometabolite 2-hydroxyglutarate (2-HG). The overproduced 2-HG can competitively inhibit α-KG-dependent dioxygenases to trigger cell differentiation disorders, a major cause of blood tumors. This review outlines recent progress in the identification of IDH2 inhibitors in blood cancer to provide a reference for ongoing and future clinical studies.

Keywords: Isocitrate dehydrogenase 2, IDH2, mutant, inhibitors, structure-activity relationship, blood cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 29 November, 2020
Page: [1113 - 1122]
Pages: 10
DOI: 10.2174/1389557520666201130102724
Price: $65

Article Metrics

PDF: 27